CONMED Corporation announced its financial results for the fourth quarter and full-year ended December 31, 2024. For the fourth quarter of 2024, net sales were $345.9 million, representing a 5.8% increase year-over-year as reported and 6.0% in constant currency. Diluted EPS for the quarter was $1.08, compared to $1.05 in Q4 2023, with adjusted diluted EPS reaching $1.34.
For the full year 2024, net sales totaled $1.307 billion, an increase of 5.0% year-over-year as reported and 5.3% in constant currency. Diluted EPS for the full year was $4.25, significantly up from $2.04 in 2023, and adjusted diluted EPS for the year was $4.17.
Looking ahead, the company provided its full-year 2025 outlook, projecting reported revenue between $1.344 billion and $1.372 billion, which translates to approximately 4% to 6% constant currency growth. Adjusted diluted net earnings per share for 2025 are expected in the range of $4.25 to $4.40, including an estimated currency headwind of $0.15 to $0.20, and excluding any potential impact from recently announced tariffs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.